Pfizer Quiver Now Bare

Stock quotes in this article: PFE , BMY  

This column was originally published on RealMoney on Dec. 4 at 7:23 a.m. ET. It's being republished as a bonus for TheStreet.com readers. For more information about subscribing to RealMoney, please click here.

Maybe they really are a bunch of jokers at Pfizer (PFE Quote). Either that, or their timing is just nightmarish. I can't believe that two days after the company discussed a new cholesterol drug at its analyst day that they scrap it.

I know most people who peripherally follow this company may ask how one far-away drug could be so important. But frankly, I didn't see anything else at Pfizer that could make up for even a fraction of the lost revenues for Lipitor.

You are now in Bristol-Myers (BMY Quote) mode for Pfizer, meaning that BMY post-Plavix going generic had surprisingly little going on. I still believe BMY may have to cut its dividend when the full brunt of 2007 losses at Plavix get realized. (Either that or sell itself to Pfizer now that Pfizer has lost its future.)

The truly nutty thing about all of this is that Pfizer's meeting last week now appears to be much ado about nothing, a manufactured guide-up that was really about one thing: Don't lose faith in Pfizer, we have this new cholesterol drug!

I panned Pfizer aggressively in these pages and the airwaves, in part because I just believe that companies with no real sales growth don't belong in peoples' portfolios. I was bombarded by people reminding me that Pfizer's about to launch this new drug that would save them.

Man, those critics must be quiet right now. As for me: as I said at the end of Confessions of a Street Addict: better to be lucky than good.

Random musings: Mark your calendar -- I've lined up two book-signing events for Jim Cramer's Mad Money: Watch TV, Get Rich and I want to see you there! On Monday, Dec. 4, come to the Barnes & Noble in Clifton, N.J. (395 Route 3 East) at 7:30 p.m. EST for some one-on-one with me. If you can't make that, I'll be in Borders Books and Music (290 Commons Way) of Bridgewater, N.J., just two nights later, Wednesday, Dec. 6, at 7 p.m. EST.

  • Loading Comments...
  •  

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin
At the time of publication, Cramer had no positions in stocks mentioned.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click here to get his second book, "You Got Screwed!" and click here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,023.42 1,069.30 2,112.44 35.03
Oil *
76.05
UP
17.46
UP
2.67
UP
7.12
DOWN
0.30
10 Yr
3.50%
SPDR Gold
107.43
+0.17%
+0.25%
+0.34%
-0.85%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services